The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation.
about
Advanced glycation end products and diabetic complicationsBeneficial effect of low ethanol intake on the cardiovascular system: possible biochemical mechanismsDual blockade of Renin Angiotensin system in reducing the early changes of diabetic retinopathy and nephropathy in a diabetic rat model.Multivariate analysis of matrix-assisted laser desorption/ionization mass spectrometric data related to glycoxidation products of human globins in nephropathic patients.Reduced fructosamine-3-kinase activity and its mRNA in human distal colorectal carcinomaInduction of RAGE shedding by activation of G protein-coupled receptors.Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney diseaseAdvanced glycation endproducts are increased in rheumatoid arthritis patients with controlled diseaseThe Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot StudAdvanced glycation end products measured by skin autofluorescence in a population with central obesityAccelerated atherosclerosis in patients with systemic autoimmune diseases.Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.Advanced glycation end products and diabetic foot disease.Advanced glycation endproducts in chronic heart failure.Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events.Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults.The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial.AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis.The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?Naturally occurring inhibitors against the formation of advanced glycation end-products.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Advanced glycation end products: role in pathology of diabetic cardiomyopathy.The role of post-translational modifications in acute and chronic cardiovascular disease.Effect of diet-derived advanced glycation end products on inflammation.Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.Advanced glycation End-products (AGEs): an emerging concern for processed food industries.Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.Heart failure with preserved ejection fraction: a nephrologist-directed primer.Increased oxidative stress and toxicity in ADH and CYP2E1 overexpressing human hepatoma VL-17A cells exposed to high glucose.Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue.Pituitary Adenylate Cyclase Activating Polypeptide, A Potential Therapeutic Agent for Diabetic Retinopathy in Rats: Focus on the Vertical Information Processing Pathway.Antibodies to age-β2 glycoprotein I in patients with anti-phospholipid antibody syndrome.Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence.Resveratrol prevents dendritic cell maturation in response to advanced glycation end productsCombined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium.Back-regulation of six oxidative stress proteins with grape seed proanthocyanidin extracts in rat diabetic nephropathy.Treatment of proteins with dietary polyphenols lowers the formation of AGEs and AGE-induced toxicity.
P2860
Q27687501-9902B60B-1857-4591-B89C-A78026CC81A0Q30360076-5223703C-EAEB-4E8E-A5BC-D6A97C6EFDB8Q30370884-A3F114D5-7D50-4697-B007-9949966F5E4BQ31107732-F989AA02-B0DB-4638-83A8-31A1BB06A3BCQ34110891-EA98EF5D-8681-4628-ACAB-AF2052096399Q34364237-D2891F12-BC33-477D-9555-0F7B975A5F70Q35214629-5A0EA929-1B2C-465A-81B5-8E5C65785219Q35907814-1BB9778B-B066-4FC3-B869-31434B5925F7Q36104828-D4234304-2488-409E-AA80-5758A1F8B3E1Q36130015-C8B147C3-C204-4F05-946E-88F1053A62CCQ36242829-7C8DADAC-983C-4693-9437-BDC452C8ACA6Q36420791-A41D9192-4142-48A3-BB62-B7B67F438EE6Q36887564-BA3C6664-2F8F-47BE-A135-3AB632B163B7Q37006353-DF171119-40F4-4A1E-B74B-E7DD893B7A98Q37149382-D21ED0B3-E727-4AC9-BDB0-1C4D78CAEFA6Q37151713-7608985C-7D84-4E32-A63F-407D8E415E1EQ37158807-2C7AD6AD-F5EC-436A-B9A5-F6CF9745D11CQ37366116-DD772770-81D7-4237-8E0B-6DB97E552696Q37445850-2A1A86F6-77AB-4890-BD74-03E02EC613D3Q37603478-21EA7C26-A284-450D-9593-5988F81FD917Q37610425-19FB6117-D24A-4B13-9740-C5CDF79A5002Q37772786-F7C08CCE-47F8-4EE2-99E6-09816CF13C7DQ37903708-586D9C56-C861-4AE5-8074-B637D5E3F113Q38070906-91902157-2F0C-4394-8061-D58214E333DBQ38081119-AB27BF91-9AA8-4622-879B-0D1A878F9C7BQ38222880-38AB71FF-4CC8-40DD-9CE9-7FDBF631A4EBQ38588208-E3A36D7A-3A85-4C5B-BD5E-7B0EA62414BCQ38603115-3A802178-C0B4-4BEE-BC06-FD2126CAD95CQ38647079-1A5DF910-B99D-47B7-A91E-B3B8D88C7C6BQ38727741-09501436-DE68-4CE2-9673-A6ED557F5BDFQ39301622-CDE073F9-DAC6-4922-8C82-BC4D5712B949Q39375888-8575A520-D840-4C71-82E2-19DC2F450661Q39797009-7EFF605E-DC96-4514-8EAF-7636D761D745Q40134757-210B2ED5-B97F-4FC8-BB97-8334E9F95837Q40858020-16AEFE50-FE83-4E15-B7E3-79C2F2702038Q42120056-DD97F454-5DAE-481E-A2BA-0856B8F305E9Q42251425-F86F5590-07AE-4536-8BAB-186E0CAAC594Q43057657-160E4D38-5E20-4BB5-9C89-B1BAEBBC99CAQ46818327-D5E6ABC9-9D88-4EAF-AF3E-B47A67DA5E95Q46840563-CB1BE4D8-1F1B-48F3-8657-6EF428E29875
P2860
The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The clinical relevance of adva ...... cs to reduce AGE accumulation.
@ast
The clinical relevance of adva ...... cs to reduce AGE accumulation.
@en
type
label
The clinical relevance of adva ...... cs to reduce AGE accumulation.
@ast
The clinical relevance of adva ...... cs to reduce AGE accumulation.
@en
prefLabel
The clinical relevance of adva ...... cs to reduce AGE accumulation.
@ast
The clinical relevance of adva ...... cs to reduce AGE accumulation.
@en
P356
P1476
The clinical relevance of adva ...... cs to reduce AGE accumulation.
@en
P2093
P304
P356
10.2174/0929867043364342
P577
2004-10-01T00:00:00Z